Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Inflammation

Asthma

Leptin

Mouse studies suggest anticholinergic compounds could help treat obesity-induced asthma. In two obesity-related mouse models of asthma, the anticholinergic agent tiotropium bromide, which inhibits parasympathetic signaling in airway smooth cells, prevented bronchoconstriction. Next steps include determining whether anticholinergic agents are effective against obesity-induced asthma.
Boehringer Ingelheim GmbH and Pfizer Inc. market Spiriva/Respimat tiotropium to treat chronic obstructive pulmonary disease (COPD). The compound is in Phase III testing to treat asthma.

SciBX 6(4); doi:10.1038/scibx.2013.91
Published online Jan. 31, 2013

Findings unpatented; unavailable for licensing

Arteaga-Solis, E. et al. Cell Metab.; published online Jan. 8, 2013;
doi:10.1016/j.cmet.2012.12.004
Contact: Gerard Karsenty, Columbia University, New York, N.Y.
e-mail:
gk2172@columbia.edu